About Authors: Ms.Komal R. Nikam (B.Pharmacy), Mr.Mahendra G. Pawar (B.Pharmacy), Mr. Kishor S. Salunkhe (M.Pharm,PhD), Mr.Devidas G.Bachhav(M.Pharm)
Amrutvahini college of pharmacy,Sangamner.(Pune University)
Abstract:
The demand for novel drug delivery technologies is ever increasing. These drug delivery technologies includes oral, transdermal, inhalation and parenteral. The main goal for the delivery of any drug therapy is oral administration with once or twice daily dosing. However, there are large numbers of therapies, particularly protein-based, gene-based vaccine-based that cannot be delivered by this route for example insulin, growth hormones and other similar biologicals.
The pitfalls of needle-based injections are well known. Psychological resistances to self-injection or needle-phobia have been documented across large demographic groups, such as diabetics. The result of this phobia is that many outpatient injectables are dosed sub-optimally. Furthermore, awareness of serious problems has caused physicians and their patients to either delay therapy initiation or seek out less-invasive alternatives, even at some cost to clinical effectiveness.
For some, especially those suffering from chronic diseases requiring injectable products two or three times a day, this process is an ongoing reality of daily life for example diabetics-accepted, but always with the hope that something new will replace the ritual of needle insertion. To overcome the problems related to needle based injections, there is one technology that has received considerable attention during the past few years and that offers all of the sought after benefits is—Needle Free Injection Technology (NFIT).